• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Danaher Completes Acquisition of Abcam

    12/6/23 7:30:00 AM ET
    $ABCM
    $DHR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Industrial Machinery/Components
    Industrials
    Get the next $ABCM alert in real time by email

    WASHINGTON, Dec. 6, 2023 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher") announced today it has completed its acquisition of Abcam plc (NASDAQ:ABCM) ("Abcam").

    The acquisition of Abcam for $24.00 per share in cash was implemented by way of a Court-sanctioned scheme of arrangement under the UK Companies Act 2006 (the "Scheme") and the Scheme became effective in accordance with its terms on December 6, 2023. As a result, Abcam has become an indirect wholly owned subsidiary of Danaher. Trading of Abcam ADSs on Nasdaq has been suspended.

    The consideration due to former Abcam shareholders will be settled pursuant to the terms of the Scheme and the consideration due to former Abcam ADS holders will be settled by the Depositary pursuant to the terms of the Deposit Agreement, in each case as further described in the shareholder circular relating to the Scheme, which was published by Abcam on October 5, 2023.

    ABOUT DANAHER

    Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our 65,000+ associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.

    Danaher Corporation, 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, D.C. 20037, Telephone: (202) 828-0850, Fax: (202) 828-0860

    Cision View original content:https://www.prnewswire.com/news-releases/danaher-completes-acquisition-of-abcam-302007456.html

    SOURCE Danaher Corporation

    Get the next $ABCM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABCM
    $DHR

    CompanyDatePrice TargetRatingAnalyst
    Danaher Corporation
    $DHR
    4/10/2025$205.00Equal Weight → Overweight
    Barclays
    Danaher Corporation
    $DHR
    3/21/2025$260.00Neutral → Buy
    Goldman
    Danaher Corporation
    $DHR
    3/14/2025$260.00Hold → Buy
    Stifel
    Danaher Corporation
    $DHR
    2/3/2025Outperform → Mkt Perform
    Raymond James
    Danaher Corporation
    $DHR
    12/23/2024Sector Perform
    Scotiabank
    Danaher Corporation
    $DHR
    12/19/2024$275.00Buy
    Guggenheim
    Danaher Corporation
    $DHR
    12/13/2024$290.00Neutral → Buy
    BofA Securities
    Danaher Corporation
    $DHR
    10/31/2024$285.00Peer Perform → Outperform
    Wolfe Research
    More analyst ratings